On Tuesday, Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) opened lower -1.43% from the last session, before settling in for the closing price of $14.69. Price fluctuations for RDY have ranged from $13.26 to $16.89 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 8.97% annually for the last half of the decade. Company’s average yearly earnings per share was noted 2.09% at the time writing. With a float of $833.01 million, this company’s outstanding shares have now reached $834.38 million.
In an organization with 27048 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 59.29%, operating margin of 22.52%, and the pretax margin is 24.1%.
Dr. Reddy’s Laboratories Ltd. ADR (RDY) Insider Updates
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Dr. Reddy’s Laboratories Ltd. ADR is 0.00%, while institutional ownership is 14.48%. The most recent insider transaction that took place on Jul 29 ’24, was worth 5,390,000.
Dr. Reddy’s Laboratories Ltd. ADR (RDY) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 2.09% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 0.74% during the next five years compared to 20.07% growth over the previous five years of trading.
Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) Trading Performance Indicators
Check out the current performance indicators for Dr. Reddy’s Laboratories Ltd. ADR (RDY). In the past quarter, the stock posted a quick ratio of 1.36. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.35. Likewise, its price to free cash flow for the trailing twelve months is 88.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.77, a number that is poised to hit 0.22 in the next quarter and is forecasted to reach 0.81 in one year’s time.
Technical Analysis of Dr. Reddy’s Laboratories Ltd. ADR (RDY)
Let’s dig in a bit further. During the last 5-days, its volume was 1.6 million. That was better than the volume of 1.07 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 55.13%. Additionally, its Average True Range was 0.25.
During the past 100 days, Dr. Reddy’s Laboratories Ltd. ADR’s (RDY) raw stochastic average was set at 18.71%, which indicates a significant decrease from 58.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 15.35% in the past 14 days, which was lower than the 20.60% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.87, while its 200-day Moving Average is $15.12. However, in the short run, Dr. Reddy’s Laboratories Ltd. ADR’s stock first resistance to watch stands at $14.57. Second resistance stands at $14.66. The third major resistance level sits at $14.72. If the price goes on to break the first support level at $14.42, it is likely to go to the next support level at $14.36. Assuming the price breaks the second support level, the third support level stands at $14.27.
Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) Key Stats
There are currently 834,727K shares outstanding in the company with a market cap of 12.06 billion. Presently, the company’s annual sales total 3,350 M according to its annual income of 668,000 K. Last quarter, the company’s sales amounted to 953,930 K and its income totaled 149,380 K.
